CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2

被引：0

作者：

Dubinsky, M. C. ^{[1
]}

Hudesman, D. P. ^{[2
]}

Steinwurz, F. ^{[3
]}

Kulisek, N. ^{[4
]}

Salese, L. ^{[4
]}

Paulissen, J. ^{[5
]}

Su, C. ^{[4
]}

Ponce de Leon, D. ^{[6
]}

Magro, F. ^{[7
,8
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] NYU, New York, NY USA

[3] Hosp Israelita Albert Einstein, Unit Inflammatory Bowel Dis, Sao Paulo, Brazil

[4] Pfizer Inc, Collegeville, PA USA

[5] Syneos Hlth, Morrisville, NC USA

[6] Pfizer Inc, Lima, Peru

[7] Univ Porto, Porto, Portugal

[8] Ctr Hosp Sao Joao, Porto, Portugal

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P366

引用

页码：S346 / S347

页数：2

共 2 条